Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

15. März 2021 13:05 ET | Quelle: Quark Venture LP

Global Health Sciences Fund (Quark Venture LP and GF Securities) Participates in $25 Million Financing for EyeYon Medical’s EndoArt® Clinical Trials Across Three Continents

VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities participated in the $25 million financing of EyeYon Medical, to advance its EndoArt®...
09. November 2020 08:00 ET | Quelle: Quark Venture LP; Global Health Sciences Fund

Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies’ IPO

VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities are pleased to announce the successful listing of portfolio company, SQZ Biotechnologies...
11. Februar 2020 08:33 ET | Quelle: Quark Venture

Global Health Sciences Fund (Quark Venture LP and GF Securities) Contributes to Volastra Therapeutics’ $12 Million Seed Financing for Company’s Development of Novel Metastatic Cancer Therapies

VANCOUVER, British Columbia, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP and GF Securities today announced that they have contributed to the $12 million seed financing to launch Volastra...
28. Januar 2020 09:00 ET | Quelle: Quark Venture

Global Health Sciences Fund (Quark Venture LP and GF Securities) Participates in $22 Million Series C Preferred Stock Financing in Raziel Therapeutics for Development of an Orphan Drug Treating Fat Disorders

VANCOUVER, British Columbia, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP and GF Securities participated in the $22 million Series C financing announced in December 2019 for Raziel...
07. Januar 2019 09:00 ET | Quelle: Quark Venture

Quark Venture Inc. and GF Securities Participate in Keros Therapeutics’ $23 million Series B Financing for Development of Therapies to Treat Debilitating Neuromuscular Diseases

VANCOUVER, British Columbia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Quark Venture Inc. (Quark) and GF Securities are pleased to announce their investment in Keros Therapeutics, a company dedicated to the...
16. Oktober 2018 09:00 ET | Quelle: Quark Venture

Quark defends its decision to cease further funding of MSI’s lead compound

VANCOUVER, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Quark Venture Inc. (“Quark”) has petitioned the British Columbia Supreme Court to overturn an unfavourable arbitration award concerning...
17. Mai 2018 13:06 ET | Quelle: Quark Venture

New medical device platform takes flight: Global Health Sciences Fund invests in Canary Medical’s proprietary, “smart” implant technology designed to improve outcomes in post-surgical patients

VANCOUVER, British Columbia, May 17, 2018 (GLOBE NEWSWIRE) -- Today, Quark Venture Inc. and GF Securities, through their Global Health Sciences Fund (GHS), announced a US$10 million investment in...
18. Dezember 2017 09:00 ET | Quelle: Quark Venture

ARTMS Products Inc. Raises US$3 Million to Advance a Safe Alternative Way to Locally Produce Medical Isotopes and Avoid Future Supply Disruptions

VANCOUVER, British Columbia, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Today, ARTMS Products Inc., the leader in the development of novel technologies which enable the production of the world’s most-used...
10. November 2017 17:16 ET | Quelle: Quark Venture

First Meeting of Health and Biosciences Economic Strategy Table identifies Canada with potential to be global economic powerhouse

VANCOUVER, British Columbia, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Karimah Es Sabar, CEO and Partner, Quark Venture, chaired the first Health and Biosciences Economic Strategy Table meeting in...
05. Oktober 2017 11:55 ET | Quelle: Quark Venture; GF Securities

Quark Venture and GF Securities Invest in Digital Technology Platform That Provides Physicians With Non-Invasive Evidence Supporting Decisions in Coronary Interventions

VANCOUVER, British Columbia, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Today, Quark Venture Inc. and GF Securities announced a US$5 million investment in CathWorks Ltd, a leader in developing non-invasive...

Nächste Seite